Title: Anti-HER2 Nanobody Labeled with 225Ac as a Potential Radiopharmaceutical for TRT
Authors: PRUSZYNSKI MarekLESZCZUK EdytaRADCHENKO ValeryJOHN Kevin DaleBRUCHERTSEIFER FrankMORGENSTERN AlfredD’HUYVETTER MatthiasLAHOUTTE Tony
Citation: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 43 no. S1 p. S177
Publisher: SPRINGER
Publication Year: 2016
JRC N°: JRC101405
ISSN: 1619-7070
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC101405
DOI: 10.1007/s00259-016-3484-4
Type: Articles in periodicals and books
Abstract: Human epidermal growth factor receptor type 2 (HER2) is overexpressed in breast, ovarian, non-small cell lung, gastric and colon cancers, and portends poor prognosis. Intact mAbs are not always ideal vectors for radioimmunotherapy due to their slow pharmacokinetic and normal-tissue clearance. Nanobodies (Nbs) are single domain antibodies derived from Camelidae. Their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and normal tissues and ease of tumor penetration make them a very attractive platform for targeted radionuclide therapy (TRT). The goal of this study was to develop and characterize a potential molecular-targeted drug based on the anti-HER2-Nb labeled with 225Ac
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.